. 2019 Mar 14;15:e00042. doi: 10.1016/j.fawpar.2019.e00042

Table 1.

Raw data from individual studies in treated areas.

First author's name	Reference	Year of publication	Country (city)	Chemical compound	Concentration in the bait	Frequency of treatment/year	Surface area in km²	Sample size at start	Positive samples at start	Sample size at end	Positive samples at end	Quality assessment (Cochrane)
First author's name	Reference	Year of publication	Country (city)	Chemical compound	Concentration in the bait	Frequency of treatment/year	Surface area in km²	Sample size at start	Positive samples at start	Sample size at end	Positive samples at end	A	B	C	D	E	F
Comte	Prev Vet Med; 111(1–2): 147–55.	2013	France (Annemasse)	Praziquantel	50 mg	5.25	33	50	NA	50	1	High	Low	Low	Low	Low	Low
Comte	Prev Vet Med; 111(1–2): 147–55.	2013	France (Pontarlier)	Praziquantel	50 mg	5.25	33	50	NA	50	4	High	Low	Low	Low	Low	Low
Schelling	Mitt Oesterr Ges Tropenmed Parasitol; 12: 185–191.	1990	Germany	Praziquantel	50 mg	3.6	6	53	2	–	–	High	Low	High	Low	Low	Low
Tsukada	Parasitology; 125(2): 119–29.	2002	Japan	Praziquantel	25 mg	12	90	156	93	74	22	Low	Low	Low	Low	Low	Low
Inoue	Vet Parasitol; 150(1–2): 88–96.	2007	Japan	Praziquantel	50 mg	12	110	56	32	45	5	High	Low	Low	Low	Low	Low
Takashi	Vet Parasitol; 198(1–2): 122–6.	2013	Japan	Praziquantel	50 mg	4.3	135	312	154	57	9	High	Low	Low	Low	Low	Low

A. sequence generation, B. allocation concealment, C. blinding, D. incomplete outcome data, E. selective outcome reporting, F. other sources of bias.